financetom
Business
financetom
/
Business
/
Veeva Systems Q4 Earnings Highlights: Revenue Beat, EPS Beat, Guidance Impresses Investors
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Veeva Systems Q4 Earnings Highlights: Revenue Beat, EPS Beat, Guidance Impresses Investors
Mar 5, 2025 2:21 PM

Shares of cloud software company Veeva Systems Inc ( VEEV ) are trading higher after the company beat analyst estimates for the fourth quarter Wednesday.

Here are the key highlights.

What Happened: Veeva ( VEEV ) reported fourth-quarter revenue of $720.9 million, up 14% year-over-year. The revenue beat a Street consensus estimate of $699.11 million according to data from Benzinga Pro.

Subscription Services revenue was $608.6 million, up 17% year-over-year.

The company reported earnings per share of $1.74 for the quarter, beating a Street estimate of $1.58.

For the full fiscal year, Veeva ( VEEV ) revenue totaled $2.75 billion, up 16% year-over-year. Subscription Services revenue was $2.29 billion for the full fiscal year, up 20% year-over-year.

"It was an outstanding quarter and year of execution and innovation in software, data, and business consulting," Veeva ( VEEV ) CEO Peter Gassner said.

Veeva ( VEEV ) ended the year with a total of 1,477 customers, including 1,125 in Veeva R&D Solutions and 730 in Veeva Commercial Solutions.

What's Next: The company said the launch of the Vault CRM Suite in December is the most advanced CRM for life sciences. AI is expected to come to the Vault CRM later this year. Over 50 customers are currently live on Vault CRM, the company said.

"These advances set us up for the significant opportunity ahead to help life sciences bring better treatments to more patients, with greater speed and efficiency. I am excited to see what we can accomplish with our customers and the Veeva ( VEEV ) team in the coming years," Gassner said.

Guidance from the company is for first-quarter revenue to be in a range of $726 million to $729 million and earnings per share of $1.74 to $1.75. Analysts expect revenue of $730.35 million and earnings per share of $1.63, according to Benzinga Pro data.

For the full fiscal year, the company is guiding for revenue in a range of $3.04 billion to $3.055 billion versus an analyst estimate of $3.055 billion. The company guides for full-year earnings per share of $7.32, versus a Street consensus estimate of $6.91.

VEEV Price Action: Veeva ( VEEV ) stock is up 6.92% to $258.93 in after-hours trading Wednesday versus a 52-week trading range of $170.25 to $258.93.

Read Next:

Remote Work Vs. Return-To-Office: Can Veeva’s Flexibility Outshine JPMorgan’s Office Mandate?

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cornish Metals Readies a Feasibility Study for its South Crofty Tin Project in the United Kingdom
Cornish Metals Readies a Feasibility Study for its South Crofty Tin Project in the United Kingdom
Mar 21, 2024
08:19 AM EDT, 03/21/2024 (MT Newswires) -- Cornish Metals ( SBWFF ) on Thursday said it is readying a feasibility study for its South Crofty tin project in the United Kingdom. The company said the study, expected to be released in the second quarter, will incorporate results of metallurgical test work, updated mine design and early-stage engineering for processing facilities....
Merck Says Keytruda Combination Misses Endpoints in Phase 3 Metastatic Lung Cancer Trial
Merck Says Keytruda Combination Misses Endpoints in Phase 3 Metastatic Lung Cancer Trial
Mar 21, 2024
08:23 AM EDT, 03/21/2024 (MT Newswires) -- Merck ( MRK ) said that a phase 3 trial of its Keytruda combined with Lynparza as a potential treatment for metastatic nonsquamous non-small cell lung cancer failed to meet its primary endpoints of overall survival and progression-free survival. Merck ( MRK ) said the safety profiles of the Keytruda and Lynparza combination...
Signal Gold Launches Strategic Process For Goldboro Project
Signal Gold Launches Strategic Process For Goldboro Project
Mar 21, 2024
08:23 AM EDT, 03/21/2024 (MT Newswires) -- Signal Gold Inc. ( SGNLF ) said Thursday that it has initiated a process with BMO Capital Markets to evaluate potential strategic alternatives to advance the Goldboro project. The company said the options could include a joint venture transaction, a merger or a sale of the company, the project, or all the assets...
Re/max Holdings Insider Bought Shares Worth $412,560, According to a Recent SEC Filing
Re/max Holdings Insider Bought Shares Worth $412,560, According to a Recent SEC Filing
Mar 21, 2024
08:22 AM EDT, 03/21/2024 (MT Newswires) -- Adam K Peterson, 10% Owner, on March 18, 2024, executed a purchase for 54,000 shares in Re/max Holdings ( RMAX ) for $412,560. Following the Form 4 filing with the SEC, Peterson has control over a total of 3,037,843 shares of the company, with 3,037,843 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1581091/000139834424006239/xslF345X03/fp0087665-1_4.xml Price: 8,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved